NCT00347646

A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)

An Open Label Sequential Dose Response Observational Study of Intravitreally Administered Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: Bausch & Lomb Incorporated · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Plasmin is expected to create a posterior vitreous detachment (PVD) when injected directly into the eye. The pharmacological creation of a PVD may be beneficial in helping to treat a variety of conditions.

Conditions

• Vitreoretinal Traction Syndrome

Interventions

Type	Name	Description
DRUG	Plasmin	27 mg of human-derived plasmin to be reconstituted with of 0.9% Sterile Sodium Chloride for a single intravitreal injection

Timeline

• Start date: 2006-09-01
• Primary completion: 2007-05-01
• Completion: 2007-06-01
• First posted: 2006-07-04
• Last updated: 2019-06-21

Locations

1 site across 1 country: United States